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Abstract
Concentration–response curves (CRCs) of adenosine receptor (AR) agonists, NECA (nonspecific),
CCPA (A1 specific), CGS-216870 (A2A specific), BAY 60-6583 (A2B specific), and Cl-IB-MECA
(A3 specific) for mesenteric arteries (MAs) from 4 AR knockout (KO) mice (A1, A2A, A2B, and
A3) and their wild type (WT) were constructed. The messenger RNA expression of MAs from KO
mice and WT were also studied. Adenosine (10−5 to 10−4 M) and NECA (10−6 to 10−5 M) induced
relaxation in all mice except A2B KO mice, which only showed constriction by adenosine at 10−6
to 10−4 and NECA at 10−8 to 10−5 M. The CCPA induced a significant constriction at 10−8 and
10−7 M in all mice, except A1KO. BAY 60-6583 induced relaxation (10−7 to 10−5 M) in WT and
no response in A2BKO except at 10−5 M. The CRCs for BAY 60-6583 in A1, A2A, and A3 KO
mice shifted to the left when compared with WT mice, suggesting an upregulation of A2B AR. No
responses were noted to CGS-21680 in all mice. Cl-IB-MECA only induced relaxation at
concentration greater than 10−7 M, and no differences were found between different KO mice. The
CRC for Bay 60-6583 was not significantly changed in the presence of 10−5 M of L-NAME, 10−6
M of indomethacin, or both. Our data suggest that A2B AR is the predominant AR subtype and the
effect may be endothelial independent, whereas A1 AR plays a significant modulatory role in
mouse MAs.
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INTRODUCTION
Mesenteric arteries are part of a network of vascular beds that regulates vascular resistance.
Mesenteric artery ischemia is often seen in people who have hardening of the arteries in
other parts of the body (for example, those with coronary artery disease or peripheral
vascular disease).1,2 The condition is more common in smokers and in patients with high
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blood pressure or plasma cholesterol.3 An imbalance between oxygen supply and demand
(ischemia) leads to alterations in cellular release of adenosine.4 Once adenosine is produced
by the action of ecto-5′-nucleotidase, it is released from the parenchymal tissue (including
endothelium) that interacts with specific extracellular receptors located on smooth muscle
and endothelial cells of the vessels to produce relaxation.5 Currently 4 adenosine receptor
(AR) subtypes, A1, A2A, A2B, and A3, are known to mediate adenosine-induced vasodilation
or vasoconstriction. Their role in coronary circulation has been extensively studied.5–9 A2A
AR is the major contributor in regulating adenosine-induced coronary vasodilation, whereas
A2B plays a minor role.5,6,8 A1 AR and A3 AR, on the other hand, negatively modulate the
A2 AR–induced vasodilation.5,7,9 However, there are very few studies that investigated the
effect of adenosine in mesenteric circulation in regard to the AR subtype that is involved in
vascular reactivity. Based upon the vessel size (about 100–200 µm outside diameter, 50–100
µm inside diameter) and relevance in blood flow regulation, the first branches of superior
mesenteric arteries in the mouse, which are considered as both conduit (feeder) and
resistance arteries in small animals,10,11 serve as a good starting vascular segment in our
study for the involvement of ARs in mesenteric artery flow regulation.
Using all 4 AR genetic knockout (KO) mice (A1, A2A, A2B, and A3) and their wild-type
(WT) controls (C57BL/6), we constructed concentration–response curves (CRCs) for
various AR agonists in submaximal preconstricted isolated mesenteric arterial rings and
profiled the messenger RNA (mRNA) expression of ARs.
MATERIALS AND METHODS
Animals
All animals were cared for in accordance with protocol approved by the Animal Care and
Use Committee of the Health Science Center at West Virginia University. A1, A2B, and A3
KO mice were obtained from Dr Stephen Tilley, University of North Carolina Chapel Hill,
Chapel Hill, NC. A2AKO mice were also obtained from Dr Stephen Tilley, but they were
originally from Dr Catherine Ledent of Universite Libre de Bruxelles, Brussels, Belgium.12
All KO mice were on C57BL/6J background. Standard laboratory food and water were
available ad libitum. Temperature was held constant at 23 ± 2°C and humidity was 60% ±
10%. An inverted light–dark cycle of 12:12 hours was used (lights off at 1700 hrs).
Experiments were conducted in accordance with national legislation and with the
Declaration of Helsinki regarding the use of experimental animals.
Materials
Adenosine, 5′-(N-ethylcarboxamido)adenosine (NECA), 2-chloro-N6-cyclopentyladenosine
(CCPA), 2-p-(2-Carboxyethyl) phenethylamino-5′-N-ethylcarboxamidoadenosine
hydrochloride hydrate (CGS-21680), 2-Chloro-N6-(3-iodobenzyl)-adenosine-5′-N-
methyluronamide (Cl-IB-MECA), phenylephrine (PE), indomethacin, L-NG-Nitroarginine
methyl ester (L-NAME), and all the chemicals for the buffers were purchased from Sigma-
Aldrich. BAY 60-6583 was a generous gift from Dr Thomas Krahn of Bayer Healthcare,
Germany. All realtime reverse transcription
Mesenteric Artery Wire Myograph Experiments
The intestines from A1, A2A, A2B, and A3, KO mice and their WT mice were excised and
placed in oxygenated (5% CO2 and 95% O2) modified Krebs–Henseleit buffer (in mM:
NaCl120, NaHCO3 25, KCl 4.7, KH2PO4 1.2, CaCl2 1.8, MgSO4 1.2, glucose 15, and
EDTA 0.05) at 37°C, pH 7.4. First-order branches of the superior mesentery arteries were
isolated and cleaned of surrounding tissue. The arterial rings (3–5 mm long, 50–100 µm
inside diameter) were mounted on an isometric myograph (Danish Myo Techology A/S,
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Aarhus, Denmark) based on the work of Mulvany and Nyborg.13 Each vascular ring was
stretched to a resting passive tension (200 mg) and was allowed to equilibrate for at least 30
minutes. The optimal resting tension was determined by measuring the tension that produced
the greatest contractile response after the addition of 50 mM KCl (determined separately).
Viability of the vascular ring was verified by recording contraction after the addition of 50
mM KCl to the tissue bath. The integrity of endothelium was confirmed by the addition of
the endothelium-dependent vasodilator acetylcholine (10−6 M) during the plateau phase of
10−6 M of PE-induced contraction, a submaximal contraction that was predetermined in
separate experiments (data not shown). Vascular rings that did not contract after the addition
of KCl or that did not relax after the addition of acetylcholine were eliminated from further
study.
After equilibration and verification of arterial ring integrity, vascular rings were randomly
assigned to 6 drug groups: adenosine, NECA (nonspecific agonist), CCPA (A1 AR agonist),
CGS-21680 (A2A AR agonist), Bay 60-6583 (A2B agonist from Bayer, Germany), and Cl-
IB-MECA (A3 AR agonist). The CRC for these adenosine analogues were obtained by
cumulative addition of the agonists in the 10−6 M PE preconstricted vascular rings. One-way
analysis of variance (ANOVA) was used to compare between mouse groups within the same
drug groups.
In separate experiments, L-NG-Nitroarginine methyl ester [L-NAME (a nitric oxide synthase
inhibitor)] and indo-methacin (a nonspecific cyclooxygenase inhibitor) were used to assess
whether endothelium plays a role in the predominant A2B AR–mediated vasodilation in the
mesenteric arteries. CRC for Bay 60-6583 was constructed, as described above, using the
vascular rings from WT mice in the presence and absence of 10−5 M L-NAME, 10−6 of
indomethacin, or both. Both of these drugs were incubated for half an hour before PE
preconstruction and subsequent cumulative dosing of Bay 60-6583.
Real-Time Reverse Transcription–Polymerase Chain Reaction Experiments
Total RNA was isolated from the first branches of mice mesenteric arteries from all 4 KO
mice and C57 using RNAEasy total RNA isolation kit from Qiagen. This was followed by
conversion of 0.5 µg of total RNA into complementary DNA (cDNA) using High Capacity
cDNA Archive Kit (Applied Biosystems, Foster City, CA) according to the instructions of
the manufacturer in a total volume of 100 µL. Because of the relatively low expression of
ARs, polymerase chain reaction (PCR) PreAmplification Kit from ABI was used. Real-time
PCR was performed using ABI PRISM 7300 Detection System (Applied Biosystems) using
Taqman Universal Mastermix (Applied Biosystems, Branchburg, NJ) according to the
instructions of the manufacturer. The reaction volume (25 µL) included 12.5 µL of 2X
Taqman Universal Mastermix, 1 µL of cDNA, and 1.25 µL of 20X FAM-labeled Taqman
gene expression assay master mix solution. For the real-time PCR for ARs genes, the
Taqman inventoried gene expression product was purchased from Applied Biosystems. The
18S ribosomal RNA was used as an endogenous control. The fold difference in expression
of target cDNA was determined using the comparative CT method. The ΔCT value was
determined in each experiment by subtracting the average 18S CT value from the
corresponding average CT for A1, A2A, A2B, and A3 AR in coronary arteries. The standard
deviation was calculated using the formula . To set the relative unit to 1, ΔΔCT
was calculated by subtraction of the ΔCT calibrator value (A1 AR ΔCT values in C57). The





.14,15 One-way ANOVA was used for comparing between mouse
groups in the same AR gene.
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All data were expressed as mean ± standard error of the mean. All CRCs were analyzed
using nonlinear regression using GraphPad Prism3. When significant differences between
curves were found, the data were further analyzed between groups at the same
concentrations. One-way ANOVA followed by Bonferroni correction for multiple
comparisons were used to analyze differences between groups. The value of P <0.05 was
considered statistically significant.
RESULTS
The CRCs for all agonists in 4 AR KO mice are shown in Figure 1. Only vasodilation was
observed using no-selective agonists (adenosine and NECA) in WT, A1, A2A, and A3 KO
mice, whereas vasoconstriction was observed only in A2B KO. CCPA, the A1 AR agonist,
induced vasoconstriction from 10−8 to 10−7 M in all KO mice except A1 KO. However, at
10−5 M, CCPA induced vasodilation in all mice possibly due to nonselective effect of CCPA
at a higher concentration. CGS-21680 had no significant vascular effect in all mice. A2B
agonist, BAY 60-6583, induced only vasodilation that is similar to adenosine and NECA in
WT mice and no effect in A2B KO mice except at 10−5 M. Interestingly, the BAY 60-6583
CRC shifted to the left in other 3 AR KO mice (A1, A2A, and A3). A3 agonist, Cl-IB-
MECA, induced vasodilation only at concentrations greater than 10−7 M, and the responses
were similar in all mice. Also, responses to acetylcholine between all mice were similar
except A3 KO that showed a significant greater response to acetylcholine (Fig. 2).
The CRC for Bay 60-6583 in WT mice was not significantly changed by the addition of
10−5 M of L-NAME, 10−6 M of indomethacin, or both (Fig. 3).
Real-time reverse transcription–polymerase chain reaction results confirm all individual KO
mice which have no expression of respective ARs. In WT mice, A2A and A2B had the
highest level of expression (3.38 ± 0.69 and 3.80 ± 075 fold of A1 AR expression). A3 AR
had the lowest expression level (0.02-fold ± 0.02-fold of A1 AR expression). We also found
that if one of the AR was deleted, the other ARs have tendency to compensate with an
increase in expression, but only 1 or 2 AR expression showed significant difference from
WT. Comparing among mice groups, only A2BKO showed a significant upregulation of A1
AR expression (Fig. 4A, about 3.5-fold more than WT) and only A1KO showed significant
A2B AR upregulation (Fig. 4C, about 2-fold more than WT). A2A AR was upregulated in
A2BKO (Fig. 4B). A3 AR expression were upregulated in A1 and A2B KO mice (Fig. 4D).
DISCUSSION
It is well established that A2A and A2B AR mediate vasodilation, whereas A1 and A3 AR
mediate vasoconstriction in adenosine-induced vascular reactivity in most vascular
tissues.5,16,17 Using genetic KO mice and specific agonists, our study provides direct
evidence that A2B AR predominantly mediates adenosine-induced vasodilation and A1 AR–
mediated vasoconstriction modulates the effect of A2B AR in mesenteric arteries, which was
also suggested in other studies.18,19
It is striking to find a complete lack of vasodilation in response to the nonspecific AR
agonists stimulation (adenosine and NECA in Figs. 1A, B) in A2BKO, which suggests an
A2B predominant effect, and a significant vasoconstriction at a higher concentration, which
implies a vasoconstriction role for other ARs. Indeed, CCPA, the A1 AR agonist, is the only
specific agonist that demonstrated a significant dose-dependent vasoconstriction (up to 10−7
M) in all KO mice and WT mice except A1KO (Fig. 1C). Previous studies from other
laboratories and ours also confirm the role of A1 AR in regulating blood pressure and
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vasoconstriction in mouse mesenteric arteries19,20 (Dovenia article). Furthermore, the lack
of vasoconstriction to adenosine and NECA in WT and the “unmasking” of the adenosine
and NECA-induced vasoconstricting effect in A2BKO strongly support the predominant role
of A2B AR and major modulatory role for A1 AR in mesenteric arteries.
The complete lack of vasodilation to CGS-21680 (Fig. 1D), an A2A specific agonist, in all
KO mice and WT mice is surprising because previous study from rabbits and some studies
in rat suggested an A2A-predominant responses in mesenteric arteries,21–23 although one
study in rat isolated and perfused mesenteric arteries did suggest a A2B AR–mediated
vasodilation.18 The differences may be due to species differences and is supported by
another study that also found little responses to CGS-21680 in isolated mouse mesenteric
arteries.19 The differences in experimental preparation (in vivo vs. in vitro and methoxamine
vs. PE preconstriction) may also explain varying results. In our experiments, only the first
branch of supramesenteric arteries was used. The further downstream branches may have
different functional profiles. Further studies are needed to investigate this observation.
The predominant role of A2B AR in this vascular preparation is obvious based upon the lack
of vasodilatory responses to BAY 60-6583, adenosine, and NECA in A2B KO. A previous
study did suggest a predominant role for A2B AR in mouse mesenteric arteries due to
observed different responses to CGS-21680 and NECA in WT mice.19 Furthermore, the
predominant role of A2B AR in this vascular tissue could also be demonstrated by the
enhanced effect of BAY 60-6583 in all KO mice except A2B KO (Fig. 1E), when compared
with WT mice.
Activation of A2B AR has been shown to have both endothelial-dependent and endothelial-
independent effects in various vascular tissues.18,24–26 Previous study in rat mesenteric
arteries demonstrated that the L-NAME had no effect on adenosine-induced vasodilation.18
To rule out the involvement of factors released from endothelium due A2B AR activation
(Bay 60-6583), in this study we used L-NAME and indomethacin. Both L-NAME and
indomethacin alone or in combination were without an effect (Fig. 3). However, it is
possible that the concentrations of these agents were not sufficient to block the release of
mediators from endothelium. Also, our data do not address the involvement of EDHF.
Therefore, further studies are needed to investigate these mechanisms.
Because A2B AR is a low-affinity AR, it has limited role under normal physiological
conditions but could play an important role under ischemic condition, where local adenosine
concentration increase significantly. Indeed, A2B AR has been shown to play a significant
role in postischemic protection.27,28 A recent study from our group found that postischemic
infarct size increases in A2B KO mice (unpublished data). However, there is limited
information on the effect of A2B AR in mesenteric ischemia. With these newly developed
A2B AR agonists,29 such as Bay 60-6583, there is renewed interest in investigating the role
of A2B AR in ischemia in this tissue.
The role of A3 AR in vascular reactivity is unclear due to its low expression (<10% of A1
AR expression in WT mice, Fig. 4D). Using Cl-IB-MECA, the A3 AR–specific agonist, we
still cannot confirm the role of A3 AR in this tissue (Fig. 1F). There is no difference between
different KO mice in response to Cl-IB-MECA including A3KO. The vasodilatory effect at
high concentration presumably indicates the nonspecific effects of Cl-IB-MECA, which is
consistent with the study showing that Cl-IB-MECA–induced vasodilation in rat mesenteric
artery cannot be blocked by A3 AR–specific antagonist, BWA-1433.30 However, we
observed a higher vasodilatory response to acetylcholine in A3KO, suggesting a possible A3
AR–mediated endothelial-dependent vasoconstricting effect. Previous study from our
laboratory has shown that the vasoconstricting effect of Cl-IB-MECA was blocked by
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COX-1 inhibitor in mouse aorta, and the expression of A3 AR and COX-1 were mostly in
endothelium.31 Although we did not observe Cl-IB-MECA–induced vasoconstriction, the
higher acetylcholine-induced vasodilatory effect in A3KO suggests A3 AR may at least
provide modulating effect to adenosine responses.
Compensatory upregulation of ARs in KO mice has been previously reported.32,33 For
instance, A2B AR has been shown to be upregulated to compensate for the removal of
predominant A2A AR in coronary arteries in A2A KO mice and vice versa.32,33 The
contractile function and the protein expression of A1 AR was found to be upregulated in
aorta from A2AKO.34 Small increases in A1, A2B, and A3 AR were found in the spleen of
A2A KO.35 In our study, we also observed an mRNA upregulation of A2A AR in A2B KO
(Fig. 4B). However, it did not translate to functional response. There is no response to
CGS-21680 in all 4 KO mice, which indicates that A2A AR may not play a significant role
in vascular reactivity in this branch of mesenteric arteries. However, it is possible that the
upregulation of A2A AR in mesenteric arteries may affect other A2A AR function, such as
reducing inflammation and KATP channel regulation.33,36,37 Alternatively, because A1 AR
was also upregulated in A2BKO (Fig. 4A), the modulating effect of A1 AR may cancel out
any effect that was induced by the A2A AR upregulation. Similarly, we observed significant
mRNA upregulation of A3 AR in A1KO (Fig. 4D), which suggested a compensatory
upregulation. However, the mRNA upregulation also did not translate to vascular functional
responses. Further investigations are needed to address these issues.
The predominant role of A2B AR and A1 AR in mesenteric arteries may have some clinical
implication. For the treatment of mesenteric ischemia, surgical revascularization remains the
treatment of choice, but thrombolytic medical treatment and vascular interventional
radiological techniques have a growing role.38 In nonocclusive mesenteric ischemia, intra-
arterial injection of papaverine to superior mesenteric artery has been shown to be effective
in preventing bowel infarct.39 At 10−6 M, A2B agonist Bay 60-6583 induces close to 90%
endothelial-independent relaxation in PE preconstricted vascular rings. A2B AR agonist may
be a viable alternative in relieving nonocclusive mesenteric ischemia.
Furthermore, mesenteric ischemia-reperfusion injury is common in surgical and trauma
patients.40 One of the preventive treatments for the injury is ischemic preconditioning (IP),
which is a phenomenon whereby exposure of a tissue to brief periods of ischemia protects
them from the deleterious effects of prolonged ischemia reperfusion (IR) injury.41 The
mechanisms of IR have been intensively studied in coronary circulation and all 4 ARs have
been shown to play prominent roles in different stages of IR.42 However, few have been
done in mesenteric circulation. Previous study in rat demonstrated that adenosine is one of
the mediators of ischemia preconditioning that ameliorate ischemia and reperfusion–induced
intestinal mucosal hyperpermeability.43 Further studies in this area are needed to clarify the
possible role of ARs in the IP and as a possible therapeutic alternative.
In conclusion, it is clear from this study that A2B AR is the predominant AR in vascular
reactivity in the first branch of superior mesenteric artery from mouse and A1 AR plays a
significant modulatory role. Although A2A AR does not play a significant role, A3 AR may
still play some role in modulating vascular reactivity. It is interesting to note that once one
AR gene was deleted, the RNA expression of other ARs had the tendency to be upregulated,
suggesting a complex compensatory relationship between ARs.
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The CRCs for the following: AR agonists—adenosine (A), NECA (B); A1 AR agonist—
CCPA (C); A2A agonist—CGS-21680 (CGS, D); A2B agonist—BAY-60-6583 (E); and A3
agonist—Cl-IB-MECA (F) in mesenteric arteries from all 4 AR KO mice and WT mice.
*Indicates significantly different from WT at the same concentration. #Indicates
significantly different from A1KO at the same concentration. $Indicates significantly
different from A2AKO. @Indicates significantly different from A3KO. P < 0.05 was
considered significant.
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Relaxation responses to 10−6 M acetylcholine in phenylnephrine preconstricted mesenteric
arteries from all 4 AR KO mice and WT mice. *Indicates significantly different from WT at
the same concentration. #Indicates significantly different from A1KO at the same
concentration. $Indicates significantly different from A2AKO.
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The effects of 10−5 M of L-NAME and 10−6 M of indomethacin on Bay 606583-induced
vascular relaxation in mesenteric artery rings from the wild-type mice. There is no
significant difference between groups. L-NAME: L-NG-nitroarginine methyl ester. Indo.:
indomethacin.
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AR mRNA expression profile of the mesenteric arteries from all 4 AR KO mice and WT
mice. *Indicates significantly difference from WT.
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